Evidence map›Paper›PMID 38347686›Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2024

Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations.

Aurash Naser-Tavakolian, Rebecca Gale, Michael Luu, John M Masterson, Abhishek Venkataramana, Dmitry Khodyakov, Jennifer T Anger, Edwin Posadas, Howard Sandler, Stephen J Freedland and 2 more

Open access · greenAbstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Developing and Assessing the Acceptability of an Information Booklet for Patients in Surveillance for Abdominal Aortic Aneurysms: An Intervention Development Study.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Aurash Naser-TavakolianDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0001-7206-0238
Rebecca GaleCedars-Sinai Center for Outcomes Research and Education (CS-CORE), Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael LuuDepartment of Biostatistics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
John M MastersonDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Abhishek VenkataramanaDepartment of Urology, University of Southern California, Los Angeles, CA, USA.
Dmitry KhodyakovRAND Institute, Santa Monica, CA, USA.ORCID 0000-0002-2818-6906
Jennifer T AngerDepartment of Urology, University of California, San Diego, San Diego, CA, USA.
Edwin PosadasDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Howard SandlerDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Stephen J FreedlandDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Brennan SpiegelCedars-Sinai Center for Outcomes Research and Education (CS-CORE), Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Timothy J DaskivichDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USRAND Corporation · USUniversity of California San Diego · USUniversity of Southern California · US

Funding

A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary MalignancyK08CA230155 · NCI · CEDARS-SINAI MEDICAL CENTER · PI DASKIVICH, TIMOTHY · 2018 to 2022
$909k
NCI NIH HHS K08 CA230155
6 · The paper itself

Abstract

backgroundPhysician treatment preference may influence how risks are communicated in prostate cancer consultations. We identified persuasive language used when describing cancer prognosis, life expectancy, and side effects in relation to a physician's recommendation for aggressive (surgery/radiation) or nonaggressive (active surveillance/watchful waiting) treatment.

methodsA qualitative analysis was performed on transcribed treatment consultations of 40 men with low- and intermediate-risk prostate cancer across 10 multidisciplinary providers. Quotes pertaining to cancer prognosis, life expectancy, and side effects were randomized. Coders predicted physician treatment recommendations from isolated blinded quotes. Testing characteristics of consensus predictions against the physician's treatment recommendation were reported. Coders then identified persuasive strategies favoring aggressive/nonaggressive treatment for each quote. Frequencies of persuasive strategies favoring aggressive/nonaggressive treatment were reported. Logistic regression quantified associations between persuasive strategies and physician treatment recommendations.

resultsA total of 496 quotes about cancer prognosis (

conclusionsPhysicians use persuasive language favoring their preferred treatment, regardless of whether their recommendation is appropriate. IMPLICATIONS: Clinicians should quantify risk so patients can judge potential harm without solely relying on persuasive language. HIGHLIGHTS: Physicians use persuasive language favoring their treatment recommendation when communicating risks of prostate cancer treatment, which may influence a patient's treatment choice.Coders predicted physician treatment recommendations based on isolated, randomized quotes about cancer prognosis, life expectancy, and side effects with 91% accuracy.Qualitative analysis revealed that when favoring nonaggressive treatment, physicians used persuasive language that amplified side effect risks and downplayed cancer risk. When favoring aggressive treatment, physicians did the opposite.Providers should be cognizant of using persuasive strategies and aim to provide quantified assessments of risk that are jointly interpreted with the patient so that patients can make evidence-based conclusions regarding risks without solely relying on persuasive language.

Indexed as

Prostatic NeoplasmsCommunicationHumansLanguageMalePersuasive CommunicationProstate-Specific AntigenQualitative ResearchProstate-Specific Antigenprostate cancerqualitative analysisrisk communicationshared decision making

Identifiers

PMID38347686
PMCPMC11102816
OpenAlexW4391782898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.